文献速递造血干细胞移植与细胞治疗

CAR NK-92细胞介导清除残留TCR+细胞以制备超纯异体TCR敲除CAR T细胞产品

CAR NK-92 cell-mediated depletion of residual TCR+ cells for ultrapure allogeneic TCR-deleted CAR T-cell products.
PubMed 文献 · Blood Adv · 2023-01-01

异体CAR T细胞治疗需破坏T细胞受体(TCR)并纯化以防移植物抗宿主病(GVHD)。研究者在体外扩增中加用基因修饰的CD3特异性CAR NK-92细胞,经两轮共培养将TCR+细胞降至<0.01%,较MACS纯化降低45倍,总产量提高约3倍且保留细胞毒活性与良好表型。

要点

  • 两轮照射后短寿命CAR NK-92细胞共培养可清除残留TCR/CD3+ T细胞。
  • 所得TCR- CAR T细胞中TCR+细胞<0.01%,较MACS纯化降低45倍。
  • 该法经NK-92饲养效应使总TCR- CAR T细胞产量提高约3倍。

核心结论

  • 这种细胞介导的纯化方法有潜力推进安全即用型CAR T细胞的临床生产。

研究设计与样本

  • 在TCRα恒定区(TRAC)基因编辑后的体外扩增过程中,加入基因修饰的CD3特异性CAR NK-92细胞系以消除残留TCR/CD3+ T细胞。

主要发现

  • 两轮连续与照射后短寿命CAR NK-92细胞共培养可产生TCR+ T细胞<0.01%的TCR- CAR T细胞。
  • 与MACS纯化相比,TCR+细胞降低45倍。
  • 通过NK-92细胞介导的饲养效应并规避MACS相关细胞丢失,总TCR- CAR T细胞产量提高约3倍。
  • 所得细胞保留细胞毒活性与良好T细胞表型。
  • 在半封闭G-Rex生物反应器中放大提供大批量生产的原理验证,改善每剂成本比。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Graft-versus-host disease (GVHD) is a major risk of the administration of allogeneic chimeric antigen receptor (CAR)-redirected T cells to patients who are HLA unmatched. Gene editing can be used to disrupt potentially alloreactive T-cell receptors (TCRs) in CAR T cells and reduce the risk of GVHD. Despite the high knockout rates achieved with the optimized methods, a subsequent purification step is necessary to obtain a safe allogeneic product. To date, magnetic cell separation (MACS) has been the gold standard for purifying TCRα/β- CAR T cells, but product purity can still be insufficient to prevent GVHD. We developed a novel and highly efficient approach to eliminate residual TCR/CD3+ T cells after TCRα constant (TRAC) gene editing by adding a genetically modified CD3-specific CAR NK-92 cell line during ex vivo expansion. Two consecutive cocultures with irradiated, short-lived, CAR NK-92 cells allowed for the production of TCR- CAR T cells with <0.01% TCR+ T cells, marking a 45-fold reduction of TCR+ cells compared with MACS purification. Through an NK-92 cell-mediated feeder effect and circumventing MACS-associated cell loss, our approach increased the total TCR- CAR T-cell yield approximately threefold while retaining cytotoxic activity and a favorable T-cell phenotype. Scaling in a semiclosed G-Rex bioreactor device provides a proof-of-principle for large-batch manufacturing, allowing for an improved cost-per-dose ratio. Overall, this cell-mediated purification method has the potential to advance the production process of safe off-the-shelf CAR T cells for clinical applications.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kath J, Du W, Martini S, et al. CAR NK-92 cell-mediated depletion of residual TCR+ cells for ultrapure allogeneic TCR-deleted CAR T-cell products. Blood Adv. 2023. PMID: 37196643. doi:10.1182/bloodadvances.2022009397

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。